A detailed history of Man Group PLC transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Man Group PLC holds 48,324 shares of FULC stock, worth $226,156. This represents 0.0% of its overall portfolio holdings.

Number of Shares
48,324
Holding current value
$226,156
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.18 - $9.74 $153,670 - $470,675
48,324 New
48,324 $172,000
Q1 2024

May 15, 2024

BUY
$6.7 - $12.0 $50,980 - $91,308
7,609 Added 8.04%
102,226 $965,000
Q4 2023

Feb 14, 2024

BUY
$3.18 - $6.86 $300,882 - $649,072
94,617 New
94,617 $638,000
Q4 2022

Feb 14, 2023

BUY
$5.01 - $8.35 $52,073 - $86,789
10,394 Added 12.12%
96,152 $699,000
Q3 2022

Nov 14, 2022

SELL
$4.92 - $9.1 $192,716 - $356,447
-39,170 Reduced 31.35%
85,758 $694,000
Q2 2022

Aug 15, 2022

BUY
$4.2 - $24.0 $524,697 - $3 Million
124,928 New
124,928 $612,000

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $244M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.